Cancer Immunotherapy: Technologies and Global Markets

Report Scope

This report provides a detailed analysis of the cancer immunotherapy market. It highlights cancer immunotherapy’s current and future market potential and analyzes the competitive environment, covering regulatory scenarios, drivers, restraints and opportunities. The report provides market trends in cancer immunotherapy for the forecast period 2024–2029 using data from 2023 and estimates from 2024. It includes projections of compound annual growth rates (CAGRs) through 2029 and provides the market shares of key players in this market.

In this analysis, the cancer immunotherapy market is segmented by therapy types, cancer types and geographic regions. By therapy type, the market is segmented into the following: checkpoint inhibitors, monoclonal antibodies, adoptive cel therapies, cytokine therapy, cancer vaccines, oncolytic virus therapy and other immunotherapies. It is segmented by cancer type into melanoma, leukemia, lymphoma, myeloma, lung cancer, breast cancer, colorectal cancer and other cancers.

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific and Rest of the World (RoW). The regional analysis includes details about major countries such as the U.S., Canada, Germany, the U.K., Italy, Spain, France, Japan, China, South Korea, Australia and India.

The report aims to:

Analyze therapies and types of cancer.

Analyze global market size and segmentation.

Understand market constraints and drivers.

Provide detailed market forecasts for 2029.

Assess market shares, competitiveness and industry structure.

Identify potential long-term impacts on the cancer immunotherapy market.

Report Includes

75 data tables and 54 additional tables

An analysis of the global cancer immunotherapy market

Analyses of the global market trends, with revenue data for 2021 to 2023, estimates for 2024, and projected CAGRs through 2029

Estimates of the market size and revenue prospects for the global market, along with a market share analysis by therapy type, cancer type, and region

Coverage of treatments that are in development for lateand early-stage oncolytic viruses, along with epidemiological information, data corresponding to cancer incidence and mortality trends

Evaluation of recent patent activity and key granted and published patents in the industry

Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies

Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

Profiles of leading companies, including Merck & Co. Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., and AstraZeneca

Companies Mentioned

ABBVIE INC.
AMGEN INC.
ASTRAZENECA
BRISTOL-MYERS SQUIBB CO.
F. HOFFMANN-LA ROCHE LTD.
GILEAD SCIENCES INC.
JOHNSON & JOHNSON SERVICES INC.
LILLY
MERCK & CO. INC.
NOVARTIS AG
PFIZER INC.
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.